ES2172535T3 - Antagonistas de los receptores de la endotelina. - Google Patents

Antagonistas de los receptores de la endotelina.

Info

Publication number
ES2172535T3
ES2172535T3 ES94915903T ES94915903T ES2172535T3 ES 2172535 T3 ES2172535 T3 ES 2172535T3 ES 94915903 T ES94915903 T ES 94915903T ES 94915903 T ES94915903 T ES 94915903T ES 2172535 T3 ES2172535 T3 ES 2172535T3
Authority
ES
Spain
Prior art keywords
antagonists
endotheline
receptors
endotheline receptors
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915903T
Other languages
English (en)
Inventor
Russell Donovan Cousins
John Duncan Elliott
Maria Amparo Lago
Jack Dale Leber
Catherine Elizabeth Peishoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2172535T3 publication Critical patent/ES2172535T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

SE DESCRIBEN NUEVOS INDANOS Y NUEVOS DERIVADOS DEL INDENO QUE SON ANTAGONISTAS DEL RECEPTOR DE LA ENDOTELINA.
ES94915903T 1993-04-27 1994-04-26 Antagonistas de los receptores de la endotelina. Expired - Lifetime ES2172535T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6681893A 1993-04-27 1993-04-27

Publications (1)

Publication Number Publication Date
ES2172535T3 true ES2172535T3 (es) 2002-10-01

Family

ID=22071916

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915903T Expired - Lifetime ES2172535T3 (es) 1993-04-27 1994-04-26 Antagonistas de los receptores de la endotelina.

Country Status (29)

Country Link
EP (1) EP0699069B9 (es)
JP (1) JP3346571B2 (es)
KR (1) KR100331667B1 (es)
CN (1) CN1129428C (es)
AP (1) AP573A (es)
AT (1) ATE213156T1 (es)
AU (1) AU682038B2 (es)
BR (1) BR9406572A (es)
CA (1) CA2160914A1 (es)
CZ (1) CZ291189B6 (es)
DE (1) DE69429861T2 (es)
DK (1) DK0699069T3 (es)
DZ (1) DZ1773A1 (es)
ES (1) ES2172535T3 (es)
FI (1) FI955103A0 (es)
HK (1) HK1012252A1 (es)
HU (2) HUT73763A (es)
IL (1) IL109443A0 (es)
MA (1) MA23172A1 (es)
NO (1) NO313754B1 (es)
NZ (1) NZ266314A (es)
PL (1) PL175392B1 (es)
PT (1) PT699069E (es)
RU (1) RU2130920C1 (es)
SG (1) SG49667A1 (es)
SI (1) SI9400195B (es)
SK (1) SK130595A3 (es)
TW (1) TW330204B (es)
WO (1) WO1994025013A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075037A (en) * 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10501812A (ja) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
WO1996020193A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
ZA969363B (en) 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
AU7677496A (en) * 1995-11-08 1997-05-29 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
WO1998008836A1 (fr) 1996-08-27 1998-03-05 Shionogi & Co., Ltd. Derives de chromene-3-carboxylate
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
CA2327928A1 (en) * 1998-04-09 1999-10-21 Merck & Co., Inc. Phosphate-mediated cyclization
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1977741A3 (en) 2004-03-17 2009-10-14 Novartis AG Use of renin inhibitors in therapy
US7423176B2 (en) 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
MX2007007482A (es) 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos como antagonistas de 5-ht.
US20100040666A1 (en) * 2005-06-24 2010-02-18 Hiroshi Azuma Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
JP4989648B2 (ja) 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2125980C1 (ru) * 1991-11-05 1999-02-10 Смитклайн Бичам Корпорейшн Антагонисты эндотелиновых рецепторов, фармкомпозиция, способ их получения, способ подавления эндотелиновых рецепторов

Also Published As

Publication number Publication date
DE69429861D1 (de) 2002-03-21
AU6775094A (en) 1994-11-21
HUT73763A (en) 1996-09-30
EP0699069A1 (en) 1996-03-06
TW330204B (en) 1998-04-21
SK130595A3 (en) 1996-06-05
FI955103A (fi) 1995-10-26
HU9501931D0 (en) 1995-09-28
AP573A (en) 1997-01-30
SI9400195A (en) 1994-12-31
JP3346571B2 (ja) 2002-11-18
IL109443A0 (en) 1994-07-31
SG49667A1 (en) 1998-06-15
NO313754B1 (no) 2002-11-25
DK0699069T3 (da) 2002-05-27
DE69429861T2 (de) 2002-09-19
BR9406572A (pt) 1996-01-30
PT699069E (pt) 2002-07-31
MA23172A1 (fr) 1994-12-31
RU2130920C1 (ru) 1999-05-27
NZ266314A (en) 1998-10-28
CZ283595A3 (en) 1996-03-13
PL311272A1 (en) 1996-02-05
CN1124923A (zh) 1996-06-19
DZ1773A1 (fr) 2002-02-17
EP0699069B1 (en) 2002-02-13
CN1129428C (zh) 2003-12-03
EP0699069B9 (en) 2003-10-22
NO954291L (no) 1995-12-21
KR100331667B1 (ko) 2002-11-08
HK1012252A1 (en) 1999-07-30
JPH08510211A (ja) 1996-10-29
SI9400195B (sl) 2003-10-31
PL175392B1 (pl) 1998-12-31
FI955103A0 (fi) 1995-10-26
CA2160914A1 (en) 1994-11-10
WO1994025013A1 (en) 1994-11-10
ATE213156T1 (de) 2002-02-15
EP0699069A4 (es) 1996-04-03
CZ291189B6 (cs) 2003-01-15
AU682038B2 (en) 1997-09-18
NO954291D0 (no) 1995-10-26
AP9400636A0 (en) 1994-04-30
HU9503067D0 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
ES2164054T3 (es) Antagonistas de receptores de endotelina.
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
MX9400071A (es) Antagonistas del receptor de endotelina.
ES2139759T3 (es) Antagonistas de citoquina.
MX9204786A (es) Antagonistas del receptor 5-ht4 y composicion farmaceutica que los contiene.
ES2196534T3 (es) Antagonistas del receptor de vitronectina.
DE69728392D1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
GR1001129B (el) Ανταγωνιστες ccκ αναλογου αμινοξεος.
NO913786L (no) Fremgangsmaate for fremstilling av fibrinogenreseptorantagonister.
DK0804440T3 (da) Tricykliske benzazapin-vasopressionantagonister
EP0539503A4 (es)
PA8431101A1 (es) Antagonistas de receptor de benzoxazinona dopamina d4.
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.
ES2195002T3 (es) Antagonistas de los receptores de la endotelina.
DE69616364D1 (de) Endothelinrezeptorantagonisten
ITMI922854A0 (it) Nuovo uso degli antagonisti dei recettori 5-ht3
MX9203778A (es) Antagonistas del receptor &-adrenergico y metodos de uso de los mismos.
IT1296975B1 (it) Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3
MX9201366A (es) Novedosos antagonistas receptores de fibrinogeno sulfonamida.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 699069

Country of ref document: ES